$141,656,003

Department of Health and Human Services·National Institutes of Health

ACTION DATE2026-03-06·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75N91021F00004_7529_75N91019D00024_7529

Award description

ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Develop an advanced universal influenza vaccine (FluMosV2) to provide broader protection against multiple flu strains.

Sub-sectors

vaccine-developmentnih-researchinfluenza

Why this matters

Universal flu vaccines could reduce annual pandemic risk and eliminate need for strain-specific reformulation, improving public health resilience.

Supply-chain signal

Large contract signals sustained demand for vaccine manufacturing, adjuvant development, and clinical trial infrastructure from biotech suppliers.

U.S.–China competition angle

Universal flu vaccine development is a strategic biotech capability; U.S. leadership here reduces dependence on foreign vaccine supply chains.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002177.

Period of performance

Start

2021-02-16

End

2031-01-28

Status

activein 1717 days

Recipient

Other awards from this recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75N91021F00004_7529_75N91019D00024_7529.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.